Previous reports have only described changes in CRegPs expression levels in the erythrocytes of CKD patients after EPO therapy with an upregulation of CD55, CD59, and CR1 in response to EPO treatment [12,13]. This evidence concerns the gene CR1 and chronic kidney disease.